Scaling the supply chain 2024

Achieving scalability: strategic insights into avoiding the pitfalls of the cell and gene therapy supply chain

Cell & Gene Therapy Insights 2024; 10(3), 205–210

DOI: 10.18609/cgti.2024.031

Published: 19 March
Donna Rill

Abi Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights, speaks to Donna Rill, Chief Technology Officer, Triumvira Immunologics. The discussion delves into the current state of the art in scaling the cell and gene therapy supply chain, emphasizing the importance of securing critical reagents, ensuring scalability for custom supply, and achieving the required scales for cGMP vector production.